TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Kennedy disease, X-linked disease, central nervous system disorder, hereditary disease, inherited neurodegenerative disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy	Recruiting	Phase 1 / Phase 2	2026-09-29		NCT07190300

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis Pharmaceuticals	432

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Carolina Urologic Research Center	Myrtle Beach	United States	55
Duke University Medical Center	Durham	United States	505
Huntsman Cancer Institute	Salt Lake City	United States	107
Medical University of South Carolina MUSC	Charleston	United States	3
Uni Of Iowa Hospitals And Clinics	Iowa City	United States	2
Univ of Alabama at Birmingham	Birmingham	United States	1
University of Kansas Cancer Center	Westwood	United States	36
Wichita Urology Group PA	Wichita	United States	2